LabCorp to Buy CRO Tandem Labs | GenomeWeb
NEW YORK (GenomeWeb News) – Laboratory Corporation of America will buy the pharmaceutical and biotechnology contract research services company Tandem Labs for an undisclosed sum, LabCorp said today.
 
Under the agreement, Burlington, NC-based LabCorp will buy all of the outstanding shares of Tandem Labs and its parent company, Northwest Toxicology. Tandem will retain its name and management structure and will operate as part of LabCorp’s Esoterix clinical trials group.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.